| HOME >> BIOLOGY >> TECHNOLOGY |
subscribers have received updates on novel genetic factors involved in
prostate cancer, breast cancer, nicotine addiction and lung cancer,
osteoporosis, intracranial and abdominal aortic aneurysm, and human
fertility and evolution.
-- Heart attack - DG051. In January, the company announced positive
results from its Phase IIa clinical testing of DG051, deCODE's
developmental compound for the prevention of heart attack. DG051,
discovered by deCODE chemists, is designed to counter risk of heart
attack by reining in the activity of the leukotriene pathway, reducing
the production of the pro-inflammatory molecule leukotriene B4 (LTB4).
The results of the Phase IIa study confirmed that DG051 delivers
significant dose-dependent reductions in LTB4 in patients with a
history of heart attack or coronary artery disease and who were taking
a variety of concomitant medications. The pharmacokinetic and safety
profiles of the compound were favorable and similar to those seen in
previous studies in healthy volunteers. The company is actively seeking
a partner with whom to take the next steps in development of its
leukotriene program.
-- Arterial thrombosis: DG041. DG041 is deCODE's novel, first-in-class
antagonist of the EP3 receptor for prostaglandins E2, being developed
as a next-generation oral anti-platelet therapy for preventing arterial
thrombosis without increasing bleeding time. In clinical studies to
date, DG041 has been shown to dramatically inhibit platelet aggregation
as well as platelet activation mediated specifically through
vasodilator-stimulated phosphoprotein (VASP), a biomarker useful for
measuring platelet activity. These effects have been shown to be
concentration-
'/>"/>
| SOURCE deCODE genetics Copyright©2008 PR Newswire. All rights reserved |